Latest Financial Results

Q2 2017

Quarter Ended Jun 30, 2017
Report Figure

Latest Report

For Fiscal Year 2016

Download Report

Stock Information

NASDAQ: ADMA

Symbol

Price

Change

Volume

52 week Low/High

Day Low/High

Company Overview

We are a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases. Our targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. Our product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at risk for certain infectious diseases.

Our goal is to be a leader in developing and commercializing specialized, targeted, plasma-derived therapeutics to extend and enhance the lives of individuals who are naturally or medically immune-compromised.

ADMA also operates ADMA BioCenters, a FDA-licensed source plasma collection facilities which provide a portion of blood plasma for the manufacture of the Company's lead product candidate RI-002.

Contact Information

Investor Relations

ADMA Biologics, Inc.
465 Route 17 South
Ramsey, NJ 07446
T: 201-478-5552
F: 201-478-5553
info@admabio.com

Transfer Agent

Continental Stock Transfer & Trust
17 Battery Place
New York, NY 10004
T: 800-509-5586
www.continentalstock.com